Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: A prospective cohort study

AIDS Research and Human Retroviruses

Volumn 24, Issue 10, 2008, Pages 1263-1268

  Martin, M ^a   Del Cacho, E ^a   Codina, C ^a   Tuset, M ^a   De Lazzari, E ^a   Mallolas, J ^a   Miro J M ^a   Gatell, J M ^a   Ribas, J ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 53849143983     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0141     Document Type: Article

References (21)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998;338:853-860.
2. Gordillo V, del Amo J, Soriano V, and González-Lahoz J . Sociodemographic and psychologic variables influencing adherence to antiretroviral therapy. AIDS 1999;13:1763-1769.
3. Knobel H, Alonso J, Casado JL, Collazos J, Gonzalez J, Ruiz I, et al.: Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA Study. AIDS 2002;16(4):605-613.
4. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al.: Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-1183.
5. De Olalla G, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, and Cayla JA: Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002;30:105-110.
6. Gross R, Bilker WB, Friedman HM, and Strom BL: Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001;15:2109-2117.
7. Townsend ML, Jackson GL, Smith R, and Wilson KH: Association between pharmacy medication refill-based adherence rates and CD4 count and viral load responses: A retrospective analysis in treatment-experienced adults with HIV. Clin Ther 2007;29:711-716.
8. Bangsberg D, Acosta E, Gupta R, Guzman D, Riley E, Harrigan P, et al.: Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006;20:223-231.
9. Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, et al.: Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005;40(1):158-163.
10. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
11. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, and Zingman BS: HIV infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007;45:4-8.
12. Bangsberg D: Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-941.
13. Codina C, Martínez M, Tuset M, del Cacho E, Martín MT, Miró JM, et al.: Comparison of three methods to calculate adherence in patients receiving antiretroviral treatment. Enferm Infecc Microbiol Clin 2002;20(10):484-490.
14. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sananndaji S, et al.: A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134:968-977.
15. Miller LG and Hays RD: Measuring adherence to antiretroviral medications in clinical trials. HIV Clin Trials 2000;1:36-46.
16. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS, et al.: Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000;23:360-361.
17. Martín MT, del Cacho E, López E, Codina C, Tuset M, de Lazzari E, Miró JM, Gatell JM, and Ribas J: Adverse side effects of antiretroviral therapy: Relationship between patients' perception and adherence. Med Clin (Barc) 2007;129(4):127-133.
18. Portsmouth S, Osorio J, McCormick K, Gazzard B, and Moyle G: Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: A 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005;6(3):185-190.
19. Claxton AJ, Cramer J, and Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-1310.
20. Moyle G: The assessing patients' preferred treatments (APPT-1) study. Int J STD AIDS 2003;14(S1):34-36.
21. Knobel H, Escobar I, Polo R, Ortega L, Martín-Conde MT, Casado JL, et al.: Recommendations from GESIDA/SEFH/PNS to improve adherence to antiviral treatment (2004). Enferm Infecc Microbiol Clin 2005;23(4):221-231.